Olmesartan medoxomil

Olmesartan medoxomil (CAS 144689-63-4), also marketed under the brand names Benicar and Olmetec, is an angiotensin II receptor blocker (ARB) prodrug used as an active pharmaceutical ingredient in antihypertensive formulations.

Developed under the research code CS-866, it is a finished API supplied to generic and branded pharmaceutical manufacturers for oral solid dosage development. The primary application is in the manufacture of oral tablets.

For the treatment of hypertension, it is formulated as a standalone or combination product, commonly paired with amlodipine or hydrochlorothiazide. Generic drug manufacturers source this API to develop bioequivalent products.

This sourcing typically follows patent expiry in key regulated markets. Contract development and manufacturing organizations (CDMOs) use it in formulation development projects requiring ICH-compliant API characterization.

Stability profiling is a critical component of these projects. Pharmaceutical importers and distributors also source it for supply into regulated markets requiring DMF or CEP documentation support for their filings.

Olmesartan medoxomil is supplied as a white to off-white crystalline powder. It is available in pharmaceutical-grade specifications aligned with USP, BP, and Ph. Eur. monographs for global compliance.

Standard commercial pack sizes range from small quantities for R&D use to bulk quantities for commercial manufacturing batches. This ensures flexibility for both pilot studies and full-scale pharmaceutical production lines.